Patients without a prior diagnosis of PCa, with elevated prostate-specific antigen and a normal digital rectal examination who underwent PHI testing prospectively prior to prostate biopsy were included in this study. PHID was calculated retrospectively using prostate volume derived from transrectal ultrasonography at biopsy. Univariable and multivariable logistic regression modelling, along with receiver-operating characteristic (ROC) curve analysis, was used to determine the ability of serum biomarkers to predict clinically significant PCa (defined as either grade group [GG] ≥2 disease or GG1 PCa detected in >2 cores or >50% of any one core) on biopsy. Age, PNB status and Prostate Imaging Reporting and Data System (PI-RADS) score were incorporated into the regression models.
Patients without a prior diagnosis of PCa, with elevated prostate-specific antigen and a normal digital rectal examination who underwent PHI testing prospectively prior to prostate biopsy were included in this study. PHID was calculated retrospectively using prostate volume derived from transrectal ultrasonography at biopsy. Univariable and multivariable logistic regression modelling, along with receiver-operating characteristic (ROC) curve analysis, was used to determine the ability of serum biomarkers to predict clinically significant PCa (defined as either grade group [GG] ≥2 disease or GG1 PCa detected in >2 cores or >50% of any one core) on biopsy. Age, PNB status and Prostate Imaging Reporting and Data System (PI-RADS) score were incorporated into the regression models.
Results
Of the 241 men who qualified for the study, 91 (37.8%) had clinically significant PCa on biopsy. The median (interquartile range) PHID was 0.74 (0.44-1.24); it was 1.18 (0.77-1.83) and 0.55 (0.38-0.89) in those with and without clinically significant PCa on biopsy, respectively (P < 0.001). On univariable logistic regression, age and PNB status were associated with clinically significant cancer. Of the tested biomarkers, PHID demonstrated the highest discriminative ability for clinically significant disease (area under the ROC curve [AUC] 0.78 for the univariable model). That continued to be the case in multivariable logistic regression models incorporating age and PNB status (AUC 0.82). At a threshold of 0.44, representing the 25th percentile of PHID in the cohort, PHID was 92.3% sensitive and 35.3% specific for clinically significant PCa; the sensitivity and specificity were 93.0% and 32.4% and 97.4% and 29.1% for GG ≥2 and GG ≥3 disease, respectively. In the 104 men who underwent MRI, PI-RADS score was complementary to PHID, with a PI-RADS score ≥3 or, if PI-RADS score ≤2, a PHID ≥0.44, detecting 100% of clinically significant disease. For that subgroup, of the biomarkers tested, PHID (AUC 0.90) demonstrated the highest discriminative ability for clinically significant disease on multivariable logistic regression incorporating age, PNB status and PI-RADS score.
Conclusions
In this contemporary cohort of men undergoing prostate biopsy for the diagnosis of PCa, PHID outperformed PHI and other PSA derivatives in the diagnosis of clinically significant cancer. Incorporating age, PNB status and PI-RADS score led to even further gains in the diagnostic performance of PHID. Furthermore, PI-RADS score was found to be complementary to PHID. Using 0.44 as a threshold for PHID, 35.3% of unnecessary biopsies could have been avoided at the cost of missing 7.7% of clinically significant cancers. Despite these encouraging results, prospective validation is needed.
Introduction
Testing using PSA has poor specificity for prostate cancer (PCa), and when used in a diagnostic setting, has been associated with a high rate of negative biopsies and overdetection of indolent disease [1, 2] . In an effort to improve the diagnosis of clinically significant disease, multiple adjunctive biomarkers have emerged, including PSA density (PSAD) [3] , which has been shown to outperform PSA for the diagnosis of clinically significant PCa [4, 5] . More recently, the Prostate Health Index (PHI), which is a composite index combining total PSA, free PSA (fPSA) and a PSA isoform, [-2]proPSA (p2PSA), has been shown to outperform total PSA in the diagnosis of clinically significant PCa [6] [7] [8] [9] . PHI assessment is approved by the US Food and Drug Administration for men with elevated total PSA level and a normal DRE.
In light of the performance of PSAD and PHI compared with PSA, our group recently investigated the ability of PHI density (PHID) to detect clinically significant PCa [10] . In a cohort of 118 men with elevated PSA levels and negative DRE undergoing prostate biopsy, 40% were found to have clinically significant PCa, defined as Gleason score (GS) ≥7 or GS 6 in >2 cores or >50% of any positive core. PHID was found to have an area under the receiver-operating characteristic (ROC) curve (AUC) of 0.84 for the diagnosis of clinically significant PCa, compared with 0.76 for PHI, 0.70 for PSAD and 0.52 for PSA. Additionally, it was found that a PHID threshold of 0.43 could be used to avoid 38% of unnecessary biopsies (and one-quarter of all biopsies) at the cost of missing 2% of clinically significant cancers and zero cancers of GS ≥ 7.
That preliminary analysis, however, was limited in that it did not consider prior negative biopsy (PNB), a simple clinical variable that has been shown to be associated with decreased risk of PCa [11] [12] [13] [14] . Furthermore, it did not consider the results of MRI, which has emerged as an important diagnostic tool both in the PNB [15] [16] [17] and the biopsy-na€ ıve [18] [19] [20] [21] setting. Gnanapragasam et al. [22] recently demonstrated the predictive ability of PHI in men who underwent repeat biopsy with systematic and MRI-guided biopsy cores. Notably, PHI was predictive even among patients with negative MRI. In an expanded clinical cohort, we therefore sought to investigate the predictive value of PHID in multivariable models considering these commonly available diagnostic tools.
Patients and Methods

Study Population and Variables
We initiated PHI testing at our institution in December 2014. All patients who underwent PHI testing were followed clinically, and short-term outcomes were tracked in a prospective database on which we have previously reported [10, 23] . PHI assessment was ordered based on provider discretion. Notably, as of October 2016, an institutional policy encouraged the use of PHI in men with negative DRE and PSA <10 ng/mL presenting for diagnostic evaluation of PCa. For all men included in the study, biopsy was performed within 6 months of serum PHI measurement. We excluded patients with abnormal DRE, as these men traditionally undergo biopsy regardless of biomarker levels. This study was approved by our institutional review board and complied with the Health Insurance Portability and Accountability Act.
Measured clinical variables included age, race, serum PSA, prostate volume, PNB status, and time from PNB. Prostate volume was measured with TRUS using the standard ellipsoid formula in all patients except for five, in whom MRI was used. Serum PSA, p2PSA and fPSA were measured using the Beckman Coulter Access â 2 immunoassay analyser, and percentage fPSA (%fPSA) was defined as [[fPSA/PSA] 9 100]. PHI was calculated using the formula [(p2PSA/fPSA) 9
. Density values were calculated as the biomarker level divided by prostate volume in mL. The index %fPSA*volume was calculated as [(%fPSA/100) 9 (prostate volume in mL)]. Multiparametric (mp)MRI of the prostate was ordered at the discretion of each urologist and results were included in the present study only if this took place no more than 6 months prior to prostate biopsy. All MRI results were graded from 1 to 5 in accordance with PI-RADS v2 guidelines [24] . If multiple lesions were present on MRI, only the highest PI-RADS score was considered.
Biopsy specimens were analysed by expert genitourinary pathologists at our institution, and were graded in accordance with 2014 International Society of Urological Pathology Consensus Conference guidelines [25] as follows: grade group (GG) 1 = GS ≤6; GG 2 = GS 3 + 4 = 7; GG 3 = GS 4 + 3 = 7; GG 4 = GS 8; GG 5 = GS 9-10. The primary outcome of this study was clinically significant PCa on biopsy, defined as either: (i) GG 1 PCa detected in >2 cores or in >50% of any one core or (ii) GG ≥ 2 disease [26] [27] [28] . Secondary outcomes included alternative definitions of clinically significant disease: GG ≥ 2 and GG ≥ 3.
Statistical Analysis
The statistical analysis methods were determined a priori. Continuous variables are reported as median and interquartile range (IQR) and were compared between groups using chisquared or Fisher's exact test, as appropriate. Categorical variables are reported as proportions and were compared between groups using the two-sample Wilcoxon rank-sum test. Univariable logistic regression was performed to determine the association between each covariate and clinically significant PCa. Multivariable logistic regression models were constructed using the covariates that were 620 © 2017 The Authors BJU International © 2017 BJU International significantly associated with clinically significant PCa on univariable analysis. As in our previous study [10] , the 25th percentile value for PHID was chosen for investigation as a potential diagnostic threshold. Accuracy of the logistic regression models was assessed using ROC analysis. All statistical comparisons were two-sided and P values <0.05 were taken to indicate statistical significance. All calculations were conducted using STATA v14 (College Station, TX, USA).
Results
Overall, 241 men met the inclusion criteria and formed the study cohort (Fig. S1 ). Of these, 91 (37.8%) had clinically significant PCa on biopsy (Table 1) . Men with clinically significant PCa were older (P = 0.015) and less likely to have had a PNB (P < 0.001). The median PSA was similar between groups (P = 0.8), while %fPSA was lower (13.5 vs 18.6; P < 0.001) and PHI was higher (46.7 vs 32.5; P < 0.001) in men with clinically significant PCa. The median prostate volume was lower in those with clinically significant PCa (42.0 vs 55.5; P < 0.001). Accordingly, PSAD (median 0.17 vs 0.12; P < 0.001) and PHID (1.18 vs 0.55) were significantly higher in the cohort with clinically significant PCa.
On univariable logistic regression, older age (odds ratio [OR] 1.04/year [95% CI: 1.01-1.07]; P = 0.020) was associated with clinically significant PCa, while race was not (Table 2) . Men who had a PNB were 70% less likely (OR 0.30 [95% CI: 0.16-0.56]; P < 0.001) to have clinically significant disease. PSA level was not predictive of clinically significant PCa, while PSAD, %fPSA, %fPSA*volume, PHI and PHID each were (all P < 0.001). Notably, each one-point increase in PHID was associated with a more than fivefold increase in the odds of clinically significant PCa on biopsy (OR 5.15 [95% CI: 2.98-8.91]; P < 0.001).
Multivariable logistic regression models including age and PNB were constructed for each biomarker, and AUC was used to measure model discriminative ability for clinically significant PCa. The baseline model including age and PNB yielded an AUC of 0.68 (Fig. 1) . The addition of PSA, %fPSA and PHI yielded AUCs of 0.70, 0.79 and 0.79, respectively. The volume-adjusted measures of PSAD and %fPSA*volume yielded AUCs of 0.76 and 0.79, respectively, while PHID yielded the highest AUC of 0.82.
In the overall cohort, the median (IQR) PHID value was 0.74 (0.44-1.24). Consistent with our previous analysis, we investigated the 25th percentile value as a diagnostic threshold for prediction of clinically significant PCa (Fig. S2) . Overall, the PHID value of 0.44 demonstrated a sensitivity of 92.3%; the negative predictive value of PHID values <0.44 was 88.3% (Table 3) . That negative predictive value increased when considering more adverse outcomes: 91.7% and 98.3% for the prediction of GG ≥ 2 and GG ≥ 3 PCa, respectively.
In addition, we sought to assess the performance of PHID in the subgroup of 104 men (43.2% of the total cohort) who underwent mpMRI. Notably, the proportion of men who underwent mpMRI was not significantly different between those who were and were not found to have clinically significant PCa on subsequent biopsy (41.8% vs 44.0%; P = 0.7). In the subgroup that underwent mpMRI, a baseline multivariable model including age, PNB and PI-RADS score yielded an AUC of 0.83 (Fig. 3) . The addition of each biomarker led to modest improvements in model AUC. The model including PSA led to minimal improvement in predictive ability (AUC = 0.85), while the model including PHID yielded the greatest improvement (AUC = 0.90).
Discussion
Prostate cancer is the most common non-cutaneous malignancy in the USA, yet most men with the disease do not die from it or ever experience its ill effects [29] . Despite this, it is the third leading cause of cancer-related death in men in the USA [29] ; thus, prevention of advanced disease remains vitally important. We know from randomized trial data [30] that PSA screening saves men from PCa-specific morbidity and mortality, which is likely to be the result of radical treatment of localized disease [31] [32] [33] ; however, some men are diagnosed with, and treated for, disease that would never have affected them [2] . The recognition of PCa Fig. 1 Receiver-operating characteristic (ROC) curve analysis for the multivariable logistic regression models for the prediction of clinically significant prostate cancer on biopsy, including the baseline model variables age and prior negative biopsy status (n = 241). PHI, Prostate Health Index; PSAD, PSA density; fPSA, free PSA. overdiagnosis and overtreatment has resulted in a shift in priorities with regard to cancer diagnosis, from diagnosing all cancer to prioritizing diagnosis of those cancers that are most likely to result in clinical sequelae [34] .
To this effect, multiple new biomarkers, including PHI, have been developed in recent years, and have shown promise in being able to more accurately differentiate clinically significant from clinically insignificant PCa than PSA [9, 35] . Loeb et al. [35] , for example, showed that using a PHI threshold of 28.6, 30.1% of unnecessary biopsies (i.e. those yielding either no cancer or clinically insignificant disease; 23% of all biopsies in their cohort) could have been avoided at the cost of missing 10.1% of clinically significant cancers. More recently, our group found that incorporating prostate volume with PHI, as PHID, led to even greater improvements in discriminative ability [10] ; however, that analysis did not incorporate another major tool, which has had a growing role in PCa diagnosis, prostate MRI [15] [16] [17] [18] [19] [20] [21] . In addition, it did not incorporate PNB status, which has been shown to influence a patient's risk of clinically significant PCa on subsequent biopsy [11, 12] . In the present study, therefore, we sought to combine all three variables in order to maximize diagnostic performance.
In the present cohort of 241 patients, twice the size of our previous study [10] , we found that PHID continued to outperform the other PSA-derived markers tested. Based on data suggesting that a 25% reduction in biopsies is a reasonable objective [36] , we chose to experiment with our expanded cohort's 25th percentile PHID value (0.44) as a potential test threshold, which was very close to our initial cohort's 25th percentile PHID value, 0.43 [10] . With the 0.44 threshold, we found that 35.3% of unnecessary biopsies could have been avoided at the cost of missing 7.7% of clinically significant cancers, using the primary definition for clinically significant PCa of GG ≥ 2 or GG 1 in >2 cores or >50% of any one core. Altering our definition of clinically significant PCa, we found that 32.4% of unnecessary biopsies could have been avoided at the cost of missing 7% of GG ≥ 2 PCa and 29.1% of unnecessary biopsies could have been avoided at the cost of missing 2.6% of GG ≥ 3 PCa. On univariable logistic regression, PHID was found to outperform all of the other biomarkers tested for the detection of clinically significant PCa (AUC 0.78). That continued to be the case in our multivariable logistic regression models incorporating age and PNB status (AUC 0.82), and, in the men who underwent MRI, age, PNB status and PI-RADS score (AUC 0.90).
Interestingly, despite our finding that PNB status was predictive of clinically significant PCa, time since PNB was not associated with that outcome (P = 0.9), suggesting that a PNB remains prognostic even years after the biopsy.
In the 104 patients who underwent mpMRI, we found that PHID and PI-RADS score were complementary: those with non-concerning PI-RADS scores (i.e. 1-2) who were found to have clinically significant PCa on biopsy had elevated PHID values, and conversely, those with low (nonconcerning) PHID values who were found to have clinically significant PCa on biopsy had concerning PI-RADS scores (i.e. [3] [4] [5] . In fact, in the men who underwent MRI, having a PI-RADS score ≥3 or, if PI-RADS score ≤2, a PHID ≥ 0.44, was 100% sensitive for clinically significant disease (Fig. 2) .
Our findings must be taken in the context of notable limitations. First, the cohort does not represent a screening population, but rather a group at elevated risk for harbouring clinically significant PCa based on demographic factors, laboratory (including PSA and PHI) values, and, where applicable, MRI findings; thus, a population that was selected for biopsy. Accordingly, the results, including the potential test threshold values, may not necessarily be applicable to the general population. Nonetheless, it is precisely the population of patients who are at high risk for clinically significant PCa based on those metrics that stands to benefit most from PHID testing. Second, similarly, whether or not to perform MRI was not standardized in this study; rather, it was left to the discretion of the treating urologist, which is a source of selection bias. Third, volumeadjusted metrics obviously require the determination of prostate volume. While prostate volume is frequently determined at the time of biopsy, via TRUS, MRI is increasingly being adopted in the pre-biopsy setting and has excellent concordance with TRUS-derived prostate volume [37] . Furthermore, in men without an MRI, office TRUS for the purpose of determining prostate volume represents a low-cost, low-risk method of determining prostate volume that is likely to be acceptable to patients if it means potentially avoiding biopsy.
In conclusion, in this contemporary cohort of men undergoing prostate biopsy for the diagnosis of PCa, PHID outperformed PHI and other PSA derivatives for the diagnosis of clinically significant PCa. Incorporating age and PNB status, and, in men who underwent MRI, age, PNB status and PI-RADS score, led to even further gains in the diagnostic performance of PHID. Furthermore, PI-RADS score was found to be complementary to PHID, and having a PI-RADS score ≥3 or, if PI-RADS score ≤2, a PHID ≥ 0.44, was 100% sensitive for clinically significant disease. Using 0.44 as a threshold for PHID, 35.3% of unnecessary biopsies could have been avoided at the cost of missing 7.7% of clinically significant cancers. Despite these encouraging results, prospective validation is needed.
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